DaVita Inc. (NYSE:DVA) Stock Position Raised by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. boosted its position in shares of DaVita Inc. (NYSE:DVA) by 201.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 74,617 shares of the company’s stock after purchasing an additional 49,885 shares during the period. Assenagon Asset Management S.A. owned 0.09% of DaVita worth $11,159,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in DVA. JPMorgan Chase & Co. boosted its position in shares of DaVita by 17.8% in the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after buying an additional 92,014 shares during the period. KBC Group NV boosted its position in DaVita by 27.3% during the 3rd quarter. KBC Group NV now owns 313,519 shares of the company’s stock worth $51,395,000 after acquiring an additional 67,250 shares during the period. BNP Paribas Financial Markets boosted its position in DaVita by 23.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 292,039 shares of the company’s stock worth $47,874,000 after acquiring an additional 56,389 shares during the period. Nordea Investment Management AB increased its holdings in shares of DaVita by 4.9% in the 4th quarter. Nordea Investment Management AB now owns 264,535 shares of the company’s stock valued at $39,712,000 after purchasing an additional 12,339 shares during the period. Finally, abrdn plc lifted its position in shares of DaVita by 1.2% in the third quarter. abrdn plc now owns 189,065 shares of the company’s stock worth $30,719,000 after purchasing an additional 2,180 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Barclays boosted their price objective on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Truist Financial upped their price target on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $161.80.

DaVita Stock Performance

Shares of DVA opened at $166.28 on Friday. The firm has a market cap of $13.63 billion, a price-to-earnings ratio of 17.94, a price-to-earnings-growth ratio of 0.75 and a beta of 0.92. The company’s fifty day moving average is $157.11 and its 200-day moving average is $152.81. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. DaVita Inc. has a 12 month low of $103.40 and a 12 month high of $169.51.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The business had revenue of $3.26 billion for the quarter, compared to analyst estimates of $3.25 billion. During the same period in the previous year, the company earned $2.85 earnings per share. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. Equities analysts expect that DaVita Inc. will post 9.71 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.